Waters Corporation (WAT)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$374.93-1.05%
Close 2026-07-07 · 1-day change
Reading WAT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track WAT free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading WAT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track WAT free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a multi-year view on a company with strong recent financial performance but fragile earnings quality and volatile management. The current state reflects a cautious optimism as the company has raised its revenue and earnings guidance.
The valuation is considered expensive compared to peers, with an expectations gap indicating that the market has priced in some level of fragility. The current premium suggests that investors are aware of the risks but still see potential in the company's growth.
Management is on track to increase full-year revenue and EPS guidance, which supports the positive trajectory. However, there is a moderate risk of missing expectations, especially given the company's history of earnings surprises trending down.
The thesis hinges on the performance of sector bellwethers like TMO, DHR, and IDXX. If these companies continue to exceed earnings expectations, it could provide a favorable environment for WAT. Conversely, any negative guidance from these peers could impact WAT's momentum.
In the next 1 to 3 years, WAT's performance will depend on its ability to maintain strong financial results and navigate sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Confidence changed from 'medium' to 'low'.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat, which indicates strong financial performance. There are no current threats affecting the thesis.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This will show if the company can maintain growth momentum after a strong Q1.
Confirms:Q2 2026 organic revenue growth was below 6.0%.
Disproves:Q2 2026 organic revenue growth was above 8.0%.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This report will provide insights on performance and guidance. It could influence stock sentiment.
Confirms one read:The earnings report shows revenue and EPS above market expectations.
Confirms the other:The earnings report shows revenue and EPS below market expectations.
Why it matters: Raising EPS guidance would show stronger profit expectations. This could boost investor confidence.
Confirms:Management raises the 2026 EPS guidance. It is now higher than before.
Disproves:Management maintains or lowers the full-year 2026 EPS guidance.
Why it matters: Success in integration will affect revenue and growth.
Confirms:Management says they are hitting revenue goals from the Biosciences purchase.
Disproves:Management reports delays or problems with revenue goals.
Why it matters: This revenue range shows how well the company is doing after the acquisition.
Confirms one read:Q2 reported revenue confirmed in the range of $1.616 billion to $1.631 billion.
Confirms the other:Q2 reported revenue falls below $1.616 billion.
Why it matters: Lower EPS guidance shows problems with making money and growth.
Confirms:Full-year 2026 adjusted EPS guidance was below $14.40.
Disproves:Full-year 2026 adjusted EPS guidance was raised above $14.60.
Why it matters: Hitting guidance shows strong demand and good integration.
Confirms:Q2 2026 total revenue is over $1.631 billion.
Disproves:Total reported revenue falls below $1.616 billion for Q2 2026.
Why it matters: Raising revenue guidance would indicate stronger sales growth. This can lead to a positive stock reaction.
Confirms:Management raises the revenue forecast for 2026. It is now higher than current estimates.
Disproves:Management keeps or lowers the full-year 2026 revenue guidance.